Pharmacokinetics

Human randomized studyAbstract inspected

A pooled, dose-normalized analysis of three randomized single-dose studies in healthy adults found that armodafinil and modafinil had similar mean terminal half-lives of about 13 hours, but armodafinil produced 33% to 40% higher total drug exposure (AUC) than modafinil on a milligram-for-milligram basis, with a monophasic rather than biphasic decline attributed to faster elimination of modafinil's S-isomer.^[1]

Terminal half-life alone does not establish an equivalent concentration-time profile or clinical interchangeability.
The analysis was conducted and authored by employees of Cephalon, Inc., which at the time marketed both armodafinil (Nuvigil) and modafinil (Provigil); this is a sponsor-funded comparison, not an independent reanalysis, and no independent replication was located in this search.
Abstract-checked; no qualified clinical review.

Inspection history

Clinical review: not reviewed by a qualified clinician.

2026-09-08 · Prior batch record retained as unverified historical input pending fresh review.

2026-09-09 · nootropic batch: reopened source(s) via NCBI E-utilities / PMC Open Access; verified and refined with precise numbers/limitations from the source.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.
Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Clin Drug Investig. 2009;29(9):613-23. DOI: 10.2165/11315280-000000000-00000. 2009. PMID:19663523 · DOI:10.2165/11315280-000000000-00000 Abstract only.
Inspected location: PubMed/MEDLINE abstract (full Background/Methods/Results/Conclusions text) via NCBI E-utilities efetch
Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts

Fresh PubMed EUtils retrieval for inherited lead PMID 19663523; identity, abstract and linked corrections checked where an abstract existed.
https://pubmed.ncbi.nlm.nih.gov/19663523/ — abstract; PubMed abstract: Results: terminal half-life comparison and later concentration-time differences; Methods: pooled single-dose studies

View this compound in the research library →

Related records in this class

Grouped under Other compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.